Tryptamine Therapeutics (ENP) AI Stock Analysis

• Market Cap: AU$53.11M
• Dividend Yield: N/A
• Average Volume (3M): 1.64M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.79
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: AU
• Employees: 50
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 1,609,510,100
• 10 Day Avg. Volume: 1,728,571
• 30 Day Avg. Volume: 1,638,927
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: AU$0.03

The score is primarily constrained by weak financial performance: zero revenue, ongoing losses, and heavy negative operating/free cash flow indicating reliance on external funding. Technicals also lean bearish (negative MACD, sub-50 RSI, and price below key moving averages). Valuation provides limited support due to negative earnings and no dividend yield data.

Tryptamine Therapeutics Business Overview & Revenue Model

Company Description

Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin currently under phase 2a clinical trial for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia and irritable bowel syndrome. The company was formerly known as Tryptamine Therapeutics Limited and changed its name to Entropy Neurodynamics Limited in November 2025. Entropy Neurodynamics Limited was founded in 2019 and is based in Camberwell, Australia.

How the Company Makes Money

Tryptamine Therapeutics Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	618.57K	99.73K	0.00
Gross Profit	-54.34K	-54.34K	-6.77K	618.57K	99.73K	-1.01M
EBITDA	-6.85M	-5.27M	-6.70M	-5.10M	-8.27M	-11.66M
Net Income	-5.33M	-5.33M	-6.14M	-7.13M	-10.08M	-8.47M
Balance Sheet
Total Assets	6.66M	6.66M	7.45M	5.88M	13.61M	21.46M
Cash, Cash Equivalents and Short-Term Investments	3.03M	3.03M	5.37M	1.64M	4.85M	12.72M
Total Debt	0.00	0.00	0.00	1.53M	3.74M	1.36M
Total Liabilities	699.17K	699.17K	1.83M	1.75M	4.81M	2.59M
Stockholders Equity	5.96M	5.96M	5.62M	4.13M	8.81M	18.87M
Cash Flow
Free Cash Flow	-7.90M	-7.90M	-6.00M	-4.03M	-9.72M	-9.51M
Operating Cash Flow	-7.77M	-7.77M	-6.00M	-4.03M	-8.59M	-7.89M
Investing Cash Flow	-133.40K	-133.40K	1.68M	-9.08K	-1.24M	-1.80M
Financing Cash Flow	5.60M	5.60M	9.27M	2.39M	1.95M	20.61M

Tryptamine Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Tryptamine Therapeutics Corporate Events

Entropy Neurodynamics Grants 10 Million Director Options to Chris Ntoumenopoulos

Entropy Neurodynamics has disclosed a change in director Chris Ntoumenopoulos’ interests, with the allotment of 10 million director options exercisable at A$0.05 and expiring on 19 December 2030. The options, issued at no consideration and approved by shareholders at the company’s 13 November 2025 meeting, increase Ntoumenopoulos’ indirect holdings and further align his remuneration with long‑term shareholder value, underscoring the company’s continued reliance on equity-based incentives to retain and incentivise key leadership as it advances its therapeutic pipeline.

Entropy Neurodynamics Issues 2 Million Unquoted Options Expiring in 2027

Entropy Neurodynamics Limited has notified the market of the issue of 2 million unquoted options, each exercisable at A$0.08 and expiring on 19 December 2027. The options, which form part of a previously announced transaction and will not be quoted on the ASX, modestly expand the company’s pool of unquoted equity and may provide additional incentive or funding flexibility for the business without immediately diluting existing shareholders in the traded ordinary shares.

Entropy Neurodynamics Issues 50 Million Unquoted Options Under Incentive Scheme

Entropy Neurodynamics has notified the ASX that it will issue 50 million unquoted options exercisable at $0.05 and expiring on 19 December 2030 under an employee incentive scheme. The move increases the company’s pool of equity-based remuneration and may help align staff incentives with long-term shareholder value, while modestly diluting existing holders if the options are ultimately exercised.

Entropy Neurodynamics Secures $847,186 R&D Tax Refund to Advance Psychedelic Therapy Trials

Entropy Neurodynamics has received an $847,186 cash refund under Australia’s R&D Tax Incentive for its FY24 eligible research and development activities, reflecting a 48.5% tax offset on qualifying expenditure. The funds will be directed to its ongoing clinical trial of TRP-8803 for binge eating disorder with Swinburne University and to the broader clinical trial program, bolstering non-dilutive funding for the company’s pipeline of psilocin-based neuropsychiatric therapies and supporting its efforts to advance TRP-8803 from promising Phase 2a data toward more commercially viable, controlled psychedelic treatments.

Entropy Neurodynamics Advances Binge Eating Disorder Trial with TRP-8803

Entropy Neurodynamics Limited has successfully completed the first patient dosing in its clinical trial for treating Binge Eating Disorder using TRP-8803, an IV-infused psilocin. This trial aims to provide controlled psychedelic experiences, which are crucial for the company’s strategy in delivering consistent psychedelic psychotherapy. The completion of this milestone, including DSMB safety clearance, sets the stage for further patient dosing and the potential for meaningful data that could support broader applications of TRP-8803 in treating eating disorders and other neuropsychiatric conditions.